Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × HER2-positive Breast Cancer × tucatinib × Clear all

Phase

Phase 3 1 Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 13 Neoplasms 3 Meningeal Neoplasms 3 Colorectal Neoplasms 3 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Rectal Neoplasms 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Colonic Neoplasms 2 Brain Neoplasms 2 Pathologic Complete Response 1 Neoplasm Metastasis 1 Metastatic Breast Cancer With a Isolated Brain Progression 1 Meningeal Carcinomatosis 1 Hemangiosarcoma 1 HER2-positive Gastric Cancer 1 HER2-positive Breast Cancer 1 Gallbladder Neoplasms 1 Esophageal Neoplasms 1 Cholangiocarcinoma 1 Adenocarcinoma Of Esophagus 1 Adenocarcinoma 1

Interventions

Trastuzumab 11 pyrotinib 8 pertuzumab 5 Docetaxel 5 Paclitaxel 2 Carboplatin 2 Capecitabine 2 tucatinib 1 trastuzumab deruxtecan 1 pegfilgrastim 1 neratinib 1 liposomal doxorubicin 1 inavolisib 1 exemestane 1 envafolimab 1 dalpiciclib 1 atezolizumab 1 Neoadjuvant Therapy 1 Metformin 1 Leuprolide 1 Goserelin 1 Fulvestrant 1 Drug Therapy 1 Anastrozole 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05955170 2025-03-27

TUC-TOC

Institut Curie

Phase 2 Recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡